https://www.globenewswire.com/news-release/2020/01/13/1969219/0/en/Verona-Pharma-Reports-Positive-Top-line-Data-in-4-Week-Phase-2b-COPD-Study-with-Nebulized-Ensifentrine-on-Top-of-Tiotropium-Therapy.html Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
Tiotropium
The Effects of RPL554 in Addition to Tiotropium in COPD Patients [Completed]
https://clinicaltrials.gov/ct2/show/NCT03028142?type=Intr https://clinicaltrials.gov/ct2/show/NCT03028142?type=Intr&cond=COPD&phase=01234&lupd_s=01%2F09%2F2019&lupd_d=14&sort=nwst The Effects of RPL554 in Addition to Tiotropium in COPD Patients Condition : Chronic Obstructive Pulmonary Disease Moderate Interventions : Drug: 1.5 mg RPL554 plus tiotropium; Drug: 6 mg RPL554 plus tiotropium; Drug: Placebo plus tiotropium Sponsor : Verona Pharma plc Completed NCT03028142 Mon, 23 Jan 2017 12:00:00 EST
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT02518139?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: TD-4208; Drug: Tiotropium Sponsor : Theravance Biopharma Completed NCT02518139 Fri, 07 Aug 2015 12:00:00 EDT
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT02459080?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: TD-4208; Drug: Placebo Sponsor : Theravance Biopharma Completed NCT02459080 Mon, 01 Jun 2015 12:00:00 EDT